Evidence map›Paper›PMID 36865194›Full record

ArticlebioRxiv : the preprint server for biology2023

Human APOBEC3B promotes tumor heterogeneity

Cameron Durfee, Nuri Alpay Temiz, Rena Levin-Klein, Prokopios P Argyris, Lene Alsøe, Sergio Carracedo, Alicia Alonso de la Vega, Joshua Proehl, Anna M Holzhauer, Zachary J Seeman and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Cameron DurfeeDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA, 78229.
Nuri Alpay TemizInstitute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA, 55455.
Rena Levin-KleinMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA, 55455.
Prokopios P ArgyrisDivision of Oral and Maxillofacial Pathology, College of Dentistry, Ohio State University, Columbus, Ohio, USA, 43210.
Lene AlsøeDepartment of Clinical Molecular Biology, University of Oslo, 0318, Oslo, Norway.
Sergio CarracedoDepartment of Clinical Molecular Biology, University of Oslo, 0318, Oslo, Norway.
Alicia Alonso de la VegaDivision of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Joshua ProehlDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA, 78229.
Anna M HolzhauerMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA, 55455.
Zachary J SeemanMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA, 55455.
Yu-Hsiu T LinDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA, 78229.
Rachel I VogelMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA, 55455.
Rocio SotilloDivision of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Hilde NilsenDepartment of Clinical Molecular Biology, University of Oslo, 0318, Oslo, Norway.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas, USA, 78229.
University of Minnesota · USThe University of Texas Health Science Center at San Antonio · USGerman Cancer Research Center · DEOslo University Hospital · NOHoward Hughes Medical Institute · USThe Ohio State University · USUniversity of Oslo · NO

Funding

PROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Reuben S Harris · 2019 to 2026
$14.5M
TRAINING IN HEMOGLOBIN &CELL MEMBRANE RESEARCHT32HL007062 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller, Gregory M Vercellotti · 1985 to 2026
$10.3M
An Interdisciplinary Training Program to Transform Graduate Education In Genetics and GenomicsT32GM140936 · NIGMS · UNIVERSITY OF MINNESOTA · PI ALBERT, FRANK WOLFGANG, GREENSTEIN, DAVID IRWIN · 2021 to 2025
$851k
Role of APOBEC3B in Epigenetic Regulation and Transformation in CancerF32CA232458 · NCI · UNIVERSITY OF MINNESOTA · PI LEVIN-KLEIN, RENA · 2018 to 2018
$59k
NCI NIH HHS F32 CA232458NCI NIH HHS P01 CA234228NHLBI NIH HHS T32 HL007062NIGMS NIH HHS T32 GM140936
6 · The paper itself

Abstract

The antiviral DNA cytosine deaminase APOBEC3B has been implicated as a source of mutation in many different cancers. Despite over 10 years of work, a causal relationship has yet to be established between APOBEC3B and any stage of carcinogenesis. Here we report a murine model that expresses tumor-like levels of human APOBEC3B after Cre-mediated recombination. Animals appear to develop normally with full-body expression of APOBEC3B. However, adult males manifest infertility and older animals of both sexes show accelerated rates of tumorigenesis (mostly lymphomas or hepatocellular carcinomas). Interestingly, primary tumors also show overt heterogeneity, and a subset spreads to secondary sites. Both primary and metastatic tumors exhibit increased frequencies of C-to-T mutations in TC dinucleotide motifs consistent with the established biochemical activity of APOBEC3B. Elevated levels of structural variation and insertion-deletion mutations also accumulate in these tumors. Together, these studies provide the first cause-and-effect demonstration that human APOBEC3B is an oncoprotein capable of causing a wide range of genetic changes and driving tumor formation

Identifiers

PMID36865194
PMCPMC9980288
OpenAlexW4322217339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.